Signal & Digital Biomarker Engine
Can low-burden behavioral signals reveal meaningful longitudinal change?
Research & R&D roadmap
Our 12-month portfolio is structured to test whether Aletheia can create trustworthy early-warning value without sacrificing usability, privacy, or calm.
The metrics below are planning targets for controlled research—not proven clinical performance, product claims, or evidence of regulatory clearance.
Can low-burden behavioral signals reveal meaningful longitudinal change?
Can the system distinguish a credible anomaly from noise while protecting sensitivity?
Can individualized models identify change while controlling false alerts and showing their reasoning?
Can people understand and act on insights without unnecessary alarm or fatigue?
Can the concept be governed, audited, and responsibly prepared for future healthcare research?
Technology roadmap
Each horizon depends on validation and governance from the horizon before it.
Signal research, longitudinal data foundations, awareness prototypes, and privacy governance.
Digital biomarkers, calibrated risk research, personalized explanations, and controlled pilots.
Subject to evidence: forecasting research, clinical workflow studies, and responsible decision support.
Long-term possibilities such as adaptive pathways and integrated systems—only if validated and appropriate.
Portfolio figure of merit
A team-developed decision measure to balance possible early-warning value with false alerts and user burden. It is not a clinical metric.
The goal is disciplined trade-offs—not accuracy at any cost.